- Home
- CUE vs CHPT Comparison
CUE vs CHPT Comparison
Compare CUE & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | CHPT |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 143.0M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CUE | CHPT |
|---|---|---|
| Price | $27.00 | $6.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $120.00 | $9.25 |
| AVG Volume (30 Days) | 160.0K | ★ 403.6K |
| Earning Date | 05-13-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $27,466,000.00 | ★ $411,224,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $16.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $4.44 |
| 52 Week High | $45.50 | $12.62 |
Technical Indicators
Market Signals| Indicator | CUE | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 51.30 |
| Support Level | $24.49 | $5.64 |
| Resistance Level | $33.73 | $6.61 |
| Average True Range (ATR) | 3.15 | 0.31 |
| MACD | -0.78 | 0.09 |
| Stochastic Oscillator | 16.97 | 93.60 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.